Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Prajapati, Parimal M.
- Metallacarboranes: Boron-Based Compounds Inhibit Key HIV Enzyme
Abstract Views :247 |
PDF Views:2
Authors
Affiliations
1 Department of Pharmaceutical and Medicinal Chemistry, Shri Sarvajanik Pharmacy College, Arvind Baug, Mehsana-384001, Gujarat, IN
1 Department of Pharmaceutical and Medicinal Chemistry, Shri Sarvajanik Pharmacy College, Arvind Baug, Mehsana-384001, Gujarat, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 2, No 3 (2010), Pagination: 205-210Abstract
Human immunodeficiency virus (HIV) is a lentivirus (a member of the retrovirus family) that causes acquired immunodeficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. Infection with HIV occurs by the transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells. The four major routes of transmission are unsafe sex, contaminated needles, breast milk, and transmission from an infected mother to her baby at birth. Metallacarboranes derived from the transition metals represent a large family of aromatic borane derivatives which, when equipped with a radiometal, are potentially useful in radioimaging and radiotherapy of tumors. The radiometallacarborane may be localized in tumor by a tumor cell-selective antibody molecule to which it is attached or by other means (biomolecule, liposome). A particular advantage of radiometallacarboranes in these applications is their extraordinarily great kinetic stability and invisibility to enzyme systems which normally degrade organic radiometal carriers (chelates) with release of the radiometal in an unwanted way.
References
- Yang, G., Paintsil, E., Dutschman, G. E., Grill, S. P., Wang, C.- J., Wang, J., Tanaka, H., Hamasaki, T., Baba, M., Cheng, Y.-C. Antimicrob. Agents Chemother. 53: 4640-4646 Kemp, D. W., Brown, J. N. (2009). Recent Advances in Pharmacotherapy.Journal of Pharmacy Practice 22: 446-466.
- Van Marck, H., Dierynck, I., Kraus, G., Hallenberger, S., Pattery, T., Muyldermans, G., Geeraert, L., Borozdina, L.,Bonesteel, R., Aston, C., Shaw, E., Chen, Q., Martinez, C.,Koka, V., Lee, J., Chi, E., de Bethune, M.-P., Hertogs, K.(2009). The Impact of Individual Human Immunodeficiency Virus Type 1 Protease Mutations on Drug Susceptibility Is Highly Influenced by Complex Interactions with the Background Protease Sequence. J. Virol. 83: 9512-9520.
- Pawlotsky, J.-M. (2009). Review: Therapeutic implications of hepatitis C virus resistance to antiviral drugs. TherapeuticAdvances in Gastroenterology 2: 205-219.
- Lynam, I., Catley, D., Goggin, K., Rabinowitz, J. L., Gerkovich,M. M., Williams, K., Wright, J., and MOTIV8, (2009). Aonomous Regulation and Locus of Control as Predictors of Antiretroviral Medication Adherence. J Health Psychol 14: 578-586.
- Aoki, M., Venzon, D. J., Koh, Y., Aoki-Ogata, H., Miyakawa, T., Yoshimura, K., Maeda, K., Mitsuya, H. (2009). Non-Cleavage Site Gag Mutations in Amprenavir-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) Predispose HIV-1 to Rapid Acquisition of Amprenavir Resistance but Delay Development of Resistance to Other Protease Inhibitors. J. Virol. 83: 3059-3068.
- Santos, A. F., Abecasis, A. B., Vandamme, A.-M., Camacho, R. J., Soares, M. A. (2009). Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G. J Antimicrob Chemother 63: 593-599.
- Marinec, P. S., Chen, L., Barr, K. J., Mutz, M. W., Crabtree, G. R., Gestwicki, J. E. (2009). FK506-binding protein (FKBP) partitions a modified HIV protease inhibitor into blood cells and prolongs its lifetime in vivo. Proc. Natl. Acad. Sci. USA 106: 1336-1341.
- Rey, D., Hoen, B., Chavanet, P., Schmitt, M. P., Hoizey, G., Meyer, P., Peytavin, G., Spire, B., Allavena, C., Diemer, M., May, T., Schmit, J. L., Duong, M., Calvez, V., Lang, J. M. (2009). High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. J Antimicrob Chemother 63: 380-388.
- Goethals, O., Clayton, R., Van Ginderen, M., Vereycken, I., Wagemans, E., Geluykens, P., Dockx, K., Strijbos, R., Smits, V., Vos, A., Meersseman, G. (2008). Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors. J. Virol. 82: 10366-10374.
- Vijay, N. N. V., Vasantika, Ajmani, R., Perelson, A. S., Dixit, N. M. (2008). Recombination increases human immunodeficiency virus fitness, but not necessarily diversity. J. Gen. Virol. 89: 1467-1477.
- Shimura, K., Kodama, E., Sakagami, Y., Matsuzaki, Y., Watanabe, W., Yamataka, K., Watanabe, Y., Ohata, Y., Doi, S., Sato, M., Kano, M., Ikeda, S., Matsuoka, M. (2008). Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137). J. Virol. 82: 764-774.
- M. Frederick Hawthorne and Andreas Maderna, "Applications of Radiolabeled Boron Clusters to the Diagnosis and Treatment of Cancer," Chem. Rev., 99, 3421 (1999).
- Akira Nakanishi, Lufeng Guan, Robert R. Kane, Harumi Kasamatsu and M. Frederick Hawthorne, "Toward a Cancer Therapy with Boron-rich Oligomeric Phosphate Diesters that Target the Cell Nucleus," Proc. Natl. Acad. Sci. USA, 96, 238, (1999).
- M. Frederick Hawthorne, "New Horizons for Therapy Based on the Boron Neutron Capture Reaction," Mol. Med. Today , 4, No. 4, 174 (1998).
- Rachel A. Watson-Clark, Mona Lisa Banquerigo, Kenneth Shelly, M. Frederick Hawthorne and Ernest L. Brahn, "Model Studies Directed Toward the Application of Boron Neutron Capture Therapy to Rheumatoid Arthritis: Boron Delivery by Liposomes to Rat Collagen-Induced Arthritis," Proc. Natl. Acad. Sci. USA, 95, 2531 (1998).
- Lufeng Guan, Letitia A. Wims, Robert R. Kane, Mark Smuckler, Sherie L. Morrison and M. Frederick Hawthorne, "Homogeneous Immunoconjugates for Boron Neutron Capture Therapy: Design, Synthesis and Preliminary Characterization," Proc. Natl. Acad. Sci. USA, 95, 13206, (1998).
- Charng-Jui Chen, Robert R. Kane, F. James Primus, Gyorgy Szalai, M. Frederick Hawthorne and John E. Shively, "Synthesis and Characterization of Oligomeric Nido-carboranyl Phosphate Diester Conjugates to Antibody and Antibody Fragments for Potential Use in Boron Neutron Capture Therapy of Solid Tumors," Bioconjugate Chem., 5, 557, (1994).
- Robert R. Kane, Karin Drechsel and M. Frederick Hawthorne, "Automated Syntheses of Carborane-Derived Homogeneous Oligophosphates: Reagents for Use in the Immunoprotein-Mediated Boron Neutron Capture Therapy (BNCT) of Cancer," J. Am. Chem. Soc., 115, 8853 (1993).
- Robert R. Kane, Christine S. Lee, Karin Drechsel, and M. Frederick Hawthorne, "Solution-Phase Synthesis of Boron-Rich Phosphates," J. Org. Chem., 58, 3227, (1993).
- Raymond J. Paxton, Barbara G. Beatty, M. Frederick Hawthorne, Aravamuthan Varadarajan, Lawrence E. Williams, Frederick L. Curtis, Carolyn B. Knobler, J. David Beatty and John E. Shively, "A Transition Metal Complex (Venus Flytrap Cluster) for Radioimmunodetection and Radioimmunotherapy," Proc. Natl. Acad. Sci., 88, 3387 (1991).
- M. Frederick Hawthorne, Aravamuthan Varadarajan, Carolyn B. Knobler, Sarmistha Chakrabarti, Raymond J. Paxton, Barbara G. Beatty and Frederick L. Curtis, "Radiometallacarboranes as Tumor Imaging Reagents," J. Am. Chem. Soc., 112, 5365 (1990).